You are here: Industry Insights > Compugen

News List

Compugen Expands Collaboration with Bristol Myers Squibb in COM701, Opdivo Study americanpharmaceuticalreview
February 26, 2021
Compugen announced the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study ...
Compugen Announces First Patient Dosed in Advanced Malignancies Trial americanpharmaceuticalreview
April 09, 2020
Compugen announced the first patient has been dosed in its Phase 1 clinical trial of COM902, an immuno-oncology therapeutic antibody targeting TIGIT, in patients with advanced malignancies.
Compugen Announces Triple Combination Study to Evaluate COM701, Opdivo, TIGIT Inhibitor americanpharmaceuticalreview
March 09, 2020
Compugen announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an investigational anti-PVRIG antibody ...
Compugen Announces Board of Directors Appointment americanpharmaceuticalreview
July 03, 2019
Compugen announced the appointment of Eran Perry to its board of directors, effective July 1, 2019. In addition, the Company announced that Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. will retire from its board of directors and will not be brought for
Compugen Doses First Patient in COM701/Opdivo® Combination Study in Patients americanpharmaceuticalreview
May 22, 2019
Compugen has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo® (nivolumab) in patients with advanced solid tumors.
Compugen Announces Issuance of Patent for COM902 americanpharmaceuticalreview
November 14, 2018
Compugen Announces Issuance of Patent for COM902
Bristol-Myers Squibb, Compugen Announce Clinical Collaboration americanpharmaceuticalreview
October 12, 2018
Bristol-Myers Squibb and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb's pro
Compugen Announces First Patient Dosed with COM701 americanpharmaceuticalreview
September 10, 2018
Compugen announced the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG.
AZ signs up for access to Compugen’s pipeline pharmatimes
July 19, 2018
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of An biospace
March 08, 2018
Selexis SA, announced today that Compugen Ltd. has taken a license to the Selexis SUREtechnology Platform™ for use in generating high-performance research cell banks (RCBs).

Previous page 1 2 Next page